ストックスクリーナーアプリを入手
1.90
1.04%
-0.02
Engene Therapeutics Inc (ENGN) 最新ニュース
Layoff Tracker: Novartis cuts New Jersey workforce again, ousting 322 employees - BioSpace
enGene reports 54% response rate in bladder cancer trial - Investing.com
Piper Sandler downgrades enGene Therapeutics (ENGN) - MSN
enGene Therapeutics Inc. Actuals & Estimates (NASDAQ:ENGN) - TradingView
enGene Therapeutics Inc. Financial Disclosures & Filings - TradingView
Enterprise value to EBITDA forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to revenue forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
ENGNenGene Therapeutics Inc Volatility & Greeks - Finviz
Price to earnings forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to EBIT forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Price to sales forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
enGene Therapeutics Inc. Actuals & Estimates (FWB:S0N0) - TradingView
ENGN Forecast — Price Target — Prediction for 2027 - TradingView
Number of shareholders of enGene Therapeutics Inc. – NASDAQ:ENGNW - TradingView
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
A Quick Look at Today's Ratings for EnGene Therapeutics(ENGN.US), With a Forecast Between $2 to $6 - Moomoo
enGene Therapeutics - The Business Journals
Morgan Stanley Downgrades EnGene to Underweight From Equalweight - Moomoo
ENGN Downgraded by Morgan Stanley -- Rating Changed to Underweig - GuruFocus
EnGene Shares Fall After Morgan Stanley Downgrade - Moomoo
enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates - Stock Titan
enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape - Streetwise Reports
EnGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says - marketscreener.com
Morgan Stanley Downgrades enGene to Underweight From Equalweight - marketscreener.com
Morgan Stanley Downgrades EnGene Therapeutics(ENGN.US) to Sell Rating - Moomoo
Morgan Stanley cuts Engene stock rating on reduced sales outlook - Investing.com
Morgan Stanley cuts Engene stock rating on reduced sales outlook By Investing.com - Investing.com UK
enGene Therapeutics (ENGN) director awarded options for 31,000 shares - Stock Titan
enGene Therapeutics (ENGN) grants director 31,000 stock options - Stock Titan
enGene Therapeutics (ENGN) director receives 31,000 stock options at $1.75 strike - Stock Titan
[Form 4] enGene Therapeutics Inc. Insider Trading Activity - Stock Titan
enGene Therapeutics (ENGN) director awarded 31,000 stock options - Stock Titan
Director Michael Heffernan of enGene (ENGN) awarded options on 31,000 shares - Stock Titan
Lota S. Zoth granted 31,000 options at enGene Therapeutics (ENGN) - Stock Titan
enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV) - The Globe and Mail
Guggenheim Maintains EnGene Therapeutics(ENGN.US) With Hold Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
EnGene slashes staff by 50% to preserve cash ahead of regulatory push - The Business Journals
ENGN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
enGene Restructures, Cuts Workforce to Advance Bladder Therapy - The Globe and Mail
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
H.C. Wainwright cuts Engene stock price target on clinical setbacks By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Engene stock price target on clinical setbacks - Investing.com
enGene Therapeutics reports Q2 2026 financial results - grafa.com
enGene (ENGN) Announces Workforce Reduction and Leadership Changes - GuruFocus
enGene Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
EnGene Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 - marketscreener.com
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
enGene Therapeutics Inc. (ENGNW) Q2 2026 Quarterly Report: Financial Highlights, Risk Factors, and Forward-Looking Statements – Minichart - Minichart
enGene Therapeutics (ENGN) Q2 2026 earnings summary - Quartr
enGene Reports Q2 2026 Results: 50% Workforce Reduction, BLA Initiation for Detalimogene in 2H 2026, $285M Cash Position, and NMIBC Clinical Updates 12 – Minichart - Minichart
enGene Therapeutics Inc. Q3 2026: Net loss $30.2M, EPS ($0.43) — 10-Q Summary - TradingView
ENGN: Net loss increased, workforce halved, and liquidity remains strong for at least 12 months - TradingView
enGene Therapeutics (ENGN) posts $60M loss, cuts workforce by 50% - Stock Titan
enGene (NASDAQ: ENGN) slashes staff 50% as it advances detalimogene BLA - Stock Titan
2.64%
大文字化:
|
ボリューム (24 時間):